Literature DB >> 10914726

Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.

J R Grandis1, D M Falkner, M F Melhem, W E Gooding, S D Drenning, P A Morel.   

Abstract

The expression of human leukocyte antigen (HLA) class I molecules on the cell surface is necessary for the presentation of peptide antigens to cytotoxic CD8+ T lymphocytes of the immune system. Down-regulation of HLA class I gene expression has been implicated in tumorigenesis, including squamous cell carcinoma of the head and neck (SCCHN). Loss of MHC class I antigens may be one mechanism by which tumor cells escape immune detection. We performed prospective immunostaining of 26 primary SCCHN tumors and samples of normal mucosa harvested several centimeters away from the primary tumor, using a large panel of antibodies directed against allele-specific as well as monomorphic determinants of HLA class I molecules. Loss of expression of HLA class I proteins in the tumor was found in 50% (13 of 26) of primary tumors and was highly correlated with HLA loss in the corresponding normal mucosa (P < 0.0001). Further analysis demonstrated that the loss of HLA class I expression in the tumor was significantly associated with regional lymph node metastases (nodal stage; P = 0.0388), and that the number of HLA class I alleles lost in the normal mucosa was associated with subsequent development of a new primary aerodigestive tract cancer (P = 0.042). A patient with two metachronous cancers available for analysis had no evidence of HLA loss in the first tumor, demonstrated allelic loss in the second cancer, and subsequently died of disease. These results suggest that the loss of expression of HLA class I alleles may have prognostic implications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10914726

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  31 in total

Review 1.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 2.  Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.

Authors:  Pooja Yesantharao; Wei Wang; Nilah M Ioannidis; Shadmehr Demehri; Alice S Whittemore; Maryam M Asgari
Journal:  Hum Immunol       Date:  2017-02-07       Impact factor: 2.850

Review 3.  T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma.

Authors:  Daniele Maggioni; Lorenzo Pignataro; Werner Garavello
Journal:  Oncoimmunology       Date:  2017-05-04       Impact factor: 8.110

Review 4.  Checkpoint immunotherapy in head and neck cancers.

Authors:  Paul Zolkind; Ravindra Uppaluri
Journal:  Cancer Metastasis Rev       Date:  2017-09       Impact factor: 9.264

5.  Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.

Authors:  Jay Friedman; Michelle Padget; John Lee; Jeffrey Schlom; James Hodge; Clint Allen
Journal:  Oral Oncol       Date:  2019-02-01       Impact factor: 5.337

6.  Super-charged NK cells inhibit growth and progression of stem-like/poorly differentiated oral tumors in vivo in humanized BLT mice; effect on tumor differentiation and response to chemotherapeutic drugs.

Authors:  Kawaljit Kaur; Paytsar Topchyan; Anna Karolina Kozlowska; Nick Ohanian; Jessica Chiang; Phyu Ou Maung; So-Hyun Park; Meng-Wei Ko; Changge Fang; Ichiro Nishimura; Anahid Jewett
Journal:  Oncoimmunology       Date:  2018-02-22       Impact factor: 8.110

7.  Tumor-derived microvesicles in sera of patients with head and neck cancer and their role in tumor progression.

Authors:  Christoph Bergmann; Laura Strauss; Eva Wieckowski; Malgorzata Czystowska; Andreas Albers; Yun Wang; Reinhard Zeidler; Stephan Lang; Theresa L Whiteside
Journal:  Head Neck       Date:  2009-03       Impact factor: 3.147

Review 8.  [Squamous cell carcinoma of the head and neck. Principles and current concepts of immunotherapy].

Authors:  T K Hoffmann; T L Whiteside; H Bier
Journal:  HNO       Date:  2005-03       Impact factor: 1.284

9.  The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines.

Authors:  Kenneth W Hance; Connie J Rogers; David A Zaharoff; Daniel Canter; Jeffrey Schlom; John W Greiner
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

10.  Immunotherapy of head and neck cancer: current and future considerations.

Authors:  Alexander D Rapidis; Gregory T Wolf
Journal:  J Oncol       Date:  2009-08-09       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.